Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Niusule Biotech, a bio-pharmaceutical company dedicated to offering pharmaceutical and nutritional supplement products to enhance both animal and human health, has acquired an additional 14% equity interest in Tianjin Behigh Pharmaceutical. The transaction increases the overall equity interest of Niusule Biotech in Tianjin Behigh to 59%.
Subscribe to our email newsletter
Amy Hu, president and CEO of Niusule, said: “We believe that the animal health products industry in China is promising and will grow rapidly in the next 10 years. Our increased stake in Tianjin Behigh is a key milestone for our company to become an important factor in China’s animal health business.
“We strongly believe the acquisition will further support our position as a leading high-quality healthcare product company in both the animal and human health markets. A key part of our business strategy is to acquire entities with an established brand, profitable operations, and a product portfolio with significant commercialization value that complement our existing business.”
Peizhu Fan, chairman and CEO of Tianjin Behigh, said: “We are pleased to be part of Niusule as it will enable us to leverage our growing marketing power and operating resources available for new animal health product launches. We look forward to the benefits associated with the acquisition and believe it provides us with a strong platform for sales and profitability growth in the future.”